Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Standard BioToolsSTU:FLB -3.87%38 Receivables Turnover is 1.41 as of Mar. 2026. GuruFocus rates STU:FLB with a GF Score™ of 38/100 and a GF Value™ of €0.45 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 811 Medical Devices & Instruments companies, Standard BioTools ranks worse than 62.15% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Standard BioTools's Revenue for the
three
months ended in Mar. 2026 was €18.29 Mil. Standard BioTools's average Accounts Receivable for the
three
months ended in Mar. 2026 was €12.93 Mil.
Hence, Standard BioTools's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.41.
Standard BioTools (STU:FLB) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Standard BioTools Receivables Turnover Related Terms
Standard BioTools Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Standard BioTools's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:FLB vs CV, ELMD, CATX: Receivables Turnover Comparison
For the Medical Devices subindustry, Standard BioTools's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Standard BioTools Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Standard BioTools's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Standard BioTools's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Standard BioTools (STU:FLB) has a Receivables Turnover of 1.41 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Standard BioTools and its competitors. According to the industry distribution chart, Standard BioTools ranks #504 out of 811 companies in the Medical Devices & Instruments industry, placing it in the top 62.1%.
Is Standard BioTools' Receivables Turnover too high?
Standard BioTools' current Receivables Turnover is 1.41. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. Standard BioTools' value of 1.41 is 74.4% below this industry median. Based on the distribution chart, Standard BioTools ranks #504 out of 811 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Standard BioTools has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Standard BioTools' Receivables Turnover compare to CV and ELMD?
According to the Medical Devices & Instruments industry distribution chart, Standard BioTools ranks #504 out of 811 companies for Receivables Turnover. This places Standard BioTools in the lower half of its industry. The industry median Receivables Turnover is 5.51. Standard BioTools' value of 1.41 is 74.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Standard BioTools's current Receivables Turnover of 1.41 is 74.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Standard BioTools and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Standard BioTools's current Receivables Turnover is 1.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Standard BioTools stock overvalued right now?
Based on GuruFocus' analysis, Standard BioTools (STU:FLB) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.45, compared to a current price of €0.75 — trading 65.6% above its estimated fair value. The current Receivables Turnover is 1.41 and 74.4% below the Medical Devices & Instruments industry median of 5.51. Standard BioTools' overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Standard BioTools (STU:FLB), the current Receivables Turnover is 1.41 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Standard BioTools (STU:FLB) Overvalued in 2026?
Based on GuruFocus' analysis, Standard BioTools stock appears to be overvalued.
The current stock price of €0.75 is trading 65.6% above its estimated GF Value™ of €0.45.
GuruFocus considers Standard BioTools to be Significantly Overvalued.
Key valuation signals for STU:FLB:
Receivables Turnover: 1.41
GF Value™: €0.45 vs. price of €0.75 (65.6% above fair value)
Industry Position: 74.4% below the Medical Devices & Instruments median (#504 of 811)
No single metric tells the full story. See the STU:FLB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
38GF Score
Get the complete analysis for STU:FLB
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:FLB has been successfully added to your 
